Theravance Biopharma’s (TBPH) “Neutral” Rating Reiterated at BTIG Research

Theravance Biopharma (NASDAQ:TBPH)‘s stock had its “neutral” rating reaffirmed by research analysts at BTIG Research in a report issued on Thursday, Benzinga reports.

Several other analysts have also issued reports on the company. JonesTrading lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 7th. Finally, HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th. Eight investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $19.40.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $17.03 on Thursday. The stock has a market cap of $884.20 million, a PE ratio of 16.86 and a beta of 0.25. Theravance Biopharma has a fifty-two week low of $13.08 and a fifty-two week high of $21.03. The stock’s 50-day moving average is $16.97 and its two-hundred day moving average is $16.45.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The company had revenue of $20.73 million for the quarter, compared to analysts’ expectations of $22.49 million. On average, equities research analysts anticipate that Theravance Biopharma will post 1.56 earnings per share for the current year.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total value of $226,737.42. Following the completion of the sale, the senior vice president directly owned 213,476 shares in the company, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the sale, the insider directly owned 9,237,279 shares of the company’s stock, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 350,011 shares of company stock worth $6,016,830. Corporate insiders own 7.65% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC acquired a new stake in shares of Theravance Biopharma in the second quarter valued at about $302,000. Groupe la Francaise acquired a new position in shares of Theravance Biopharma during the 2nd quarter worth about $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Theravance Biopharma during the 2nd quarter valued at approximately $1,071,000. GTS Securities LLC acquired a new stake in Theravance Biopharma in the 2nd quarter valued at approximately $430,000. Finally, Hsbc Holdings PLC increased its position in Theravance Biopharma by 14.4% in the 2nd quarter. Hsbc Holdings PLC now owns 49,428 shares of the biopharmaceutical company’s stock worth $843,000 after buying an additional 6,224 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.